Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
Treatment
Study for women with relapsed platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer who responded to their most recent platinum chemotherapy
Clinicaltrials.gov identifier:NCT06888921
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]
About the Study
This study tests whether COM701 (an anti‑PVRIG ) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, , or primary peritoneal cancer are 2:1 to COM701 or . Visits include regular safety checks and scans. The trial is open at multiple centers in the U.S., France, and Israel.
This Study is Open To:
You may be eligible if you:
- Are 18 or older and female
- Have relapsed platinum‑sensitive epithelial ovarian, , or primary peritoneal cancer.
- Completed 2 or more prior platinum‑based treatment courses.
- In your most recent platinum regimen, received 4 or more cycles and achieved a partial or complete response.
- Previously received bevacizumab or a if eligible, and are not a candidate for (or declined) these options now.
- Have recovered from prior treatment side effects to Grade ≤1 (except ; neuropathy ≤Grade 2).
This Study is NOT Open To:
You would not be eligible if you:
- Have had 4 or more total lines of cytotoxic chemotherapy.
- Received checkpoint inhibitors before (PD‑1/PD‑L1, anti‑PVRIG, TIGIT, etc.).
- Need immunosuppressive systemic steroids (or similar) within 2 weeks before first dose.
- Have liver metastases at the start or end of the current platinum line.
- Required ascites drainage during the last two cycles of your most recent chemo or after finishing it.
- Had a bowel obstruction in the past 6 weeks.
- Have active CNS metastases, active HBV/HCV/HIV, or an uncontrolled infection.
- Are pregnant/breastfeeding, or received a live vaccine within 30 days of starting.
What the Study Involves
This is a , double‑blind, placebo‑controlled, parallel‑group maintenance trial.
- Screening/qualification: Medical history review, physical exam, labs/urine, ECG, baseline CT/MRI (within ~28 days), and tumor tissue (archival preferred; fresh biopsy if needed).
- Treatment & schedule:
- COM701 (IV) or IV every 3 weeks, up to ~2 years (max 35 doses).
- Routine visit assessments: physical exam, vitals, labs (including thyroid/liver/kidney), CA‑125, periodic ECG and per schedule.
- Imaging/monitoring:
- Year 1: scans every 9 weeks;
- Year 2: every 12 weeks;
- Additional scans if clinically indicated or at the end of treatment.
- Research samples: PK and ADA blood samples (e.g., Cycle 1, 6, 12, and 30 days post‑last dose). Optional tumor biopsy around Cycle 2/3.
- Follow‑up: End‑of‑treatment visit within 7 days; safety follow‑up at Day 30 (visit) and Days 60 & 90 (calls). If stopping for reasons other than progression, scans are performed every 9 weeks up to 1 year.
- Compensation: ask your site about reimbursement for travel/parking or other costs.
- Additional time beyond standard care: Clinic infusion every 3 weeks with research blood draws and scheduled imaging as above
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]
Locations:
Georgia
City: Augusta RECRUITING
Facility: Georgia Cancer Center at Augusta University
Contact Info:
[email protected]
(706) 721-8978
Illinois
City: Chicago RECRUITING
Facility: The University of Chicago Medical Center
Contact Info:
[email protected]
773-702-6216
City: Warrenville RECRUITING
Facility: Northwestern Memorial Hospital
Contact Info:
[email protected]
630-352-5360
Massachusetts
City: Boston RECRUITING
Facility: Massachusetts General Hospital
Contact Info:
[email protected]
617-726-5085
Michigan
City: Grand Rapids RECRUITING
Facility: Corewell Health
Contact Info:
[email protected]
(616) 391-1774
North Carolina
City: Charlotte RECRUITING
Facility: Levine Cancer Institute
Contact Info:
[email protected]
980-442-2333
New York
City: New York RECRUITING
Facility: Memorial Sloan Kettering Cancer Center- Main Campus
Contact Info:
[email protected]
(347) 798-9213
City: Rochester RECRUITING
Facility: University of Rochester Medical Center
Contact Info:
[email protected]
(585) 442-8020
Ohio
City: Hilliard RECRUITING
Facility: Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
Contact Info:
[email protected]
(614) 814-9717
Oklahoma
City: Oklahoma City RECRUITING
Facility: OU Health Stephenson Cancer Center
Contact Info:
[email protected]
405-271-8707
Pennsylvania
City: Pittsburgh RECRUITING
Facility: UPMC Magee- Womens Hospital
Contact Info:
[email protected]
412-641-3575
South Dakota
City: Sioux Falls RECRUITING
Facility: Avera Cancer Institute
Contact Info:
[email protected]
(605) 322-3000
Virginia
City: Charlottesville RECRUITING
Facility: UVA Comprehensive Cancer Center
Contact Info:
[email protected]
(434) 924-9333
Other Countries
Country: France
City: Lille RECRUITING
Facility: Centre Oscar Lambret
Contact Info:
[email protected]
03 20 29 56 15
Country: France
City: Marseille RECRUITING
Facility: Institut Paoli-Calmettes
Contact Info:
[email protected]
+33 4 91 22 33 33
Country: France
City: Pierre-Bénite RECRUITING
Facility: Hospices Civils de Lyon- Centre Hospitalier Lyon Sud
Contact Info:
[email protected]
+33 4 78 86 43 24
Country: France
City: Rennes RECRUITING
Facility: Centre Eugene Marquis
Contact Info:
[email protected]
+33 2 99 25 3261
Country: France
City: Saint-Herblain RECRUITING
Facility: Institut de Cancerologie de l'Ouest- Site Rene Gauducheau
Contact Info:
[email protected]
+33 2 40 67 99 00
Country: France
City: Villejuif RECRUITING
Facility: Gustave Roussy
Contact Info:
[email protected]
+33 1 42 11 42 11
Country: France
State: France
City: Besançon RECRUITING
Facility: Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
Contact Info:
[email protected]
03.70.63.20.89
Country: France
State: France
City: Toulouse RECRUITING
Facility: Oncopole Claudius Regaud
Contact Info:
[email protected]
+33 5 31 15 58 10
Country: Israel
City: Ashdod RECRUITING
Facility: Assuta Medical Center
Contact Info:
[email protected]
+972723399915
Country: Israel
City: Haifa RECRUITING
Facility: Rambam Health Care Campus
Contact Info:
[email protected]
+972-4-7776731
Country: Israel
City: Holon RECRUITING
Facility: The Edith Wolfson Medical Center
Contact Info:
[email protected]
97235028408
Country: Israel
City: Jerusalem RECRUITING
Facility: Shaare Zedek Medical Center
Contact Info:
[email protected]
+97226555727
Country: Israel
City: Jerusalem RECRUITING
Facility: Hadassah, University Hospital Ein Kerem
Contact Info:
[email protected]
+972-52-6754586
Country: Israel
City: Ramat Gan RECRUITING
Facility: The Chaim Sheba Medical Center
Contact Info:
[email protected]
+972 54 5805380
Treatment
Study for women with relapsed platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer who responded to their most recent platinum chemotherapy
Clinicaltrials.gov identifier:NCT06888921
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]